Market research
ASP.TO Acerus Pharmaceuticals Corporation
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 0.38
- Dividend yield
- 0.0%
- Beta
- 1.03
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA00444G4051
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 0.38
- Dividend yield
- 0.0%
- Beta
- 1.03
About
About Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ASP.TO discussion.
5 years, 5 months ago
Acerus Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 8.5% above its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.4.
Acerus Pharmaceuticals Corporation's total revenue sank by 47.3% to $271K since the same quarter in the previous year.
Its net income has dropped by 82.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 13.0% to $-5M since the same quarter in the previous year.
Based on the above factors, Acerus Pharmaceuticals Corporation gets an overall score of 2/5.